Is CME a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for CME Group (CME) rests on Record trading volumes: Average daily volume hit a record 36.2 million contracts in Q1 2026, up 22 percent year over year with records across all six asset classes, and revenue reached a record ~$1.88 billion. The bear case rests on revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Analysts covering it publish targets from $218.00 to $337.00 against a $293.87 price, so even the professionals disagree by 41% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results. The investment picture is that of a wide-moat, capital-light franchise with operating margins near 65 to 70 percent and heavy free-cash-flow generation, which funds a regular quarterly dividend plus a variable year-end dividend that together produce a high headline yield. The trade-offs are a full valuation for an exchange, sensitivity to interest-rate activity and volatility cycles, and emerging competitive and regulatory threats (FMX in Treasury futures, perpetual-futures offerings from crypto venues) that could pressure the moat over time. As of 16 October 2026 the shares closed at ~$290.98, up ~7.9% year to date and ~10.8% over twelve months, for a market value near ~$105 billion and about 25 times trailing earnings. The second quarter of 2026 cooled after a record first quarter: revenue of ~$1.71 billion against ~$1.88 billion in Q1, with adjusted EPS of ~$2.99 beating the ~$2.91 consensus. Third-quarter results are due on 21 October 2026, where analysts expect ~$2.98 a share on ~$1.71 billion of revenue.
The bull case: what would have to be true for $337.00
The most optimistic published target on CME is $337.00, +14.7% from the $293.87 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Record trading volumes
Average daily volume hit a record 36.2 million contracts in Q1 2026, up 22 percent year over year with records across all six asset classes, and revenue reached a record ~$1.88 billion. The second quarter was quieter, at ~$1.71 billion of revenue, roughly flat year over year (~0.8% growth). Because CME earns a fee per contract, volume flows almost directly to revenue given the fixed-cost, capital-light model, which is also why a calmer quarter shows up quickly in the top line.
2. Interest-rate and volatility franchise
CME's interest-rate complex (SOFR, Treasury futures) is its largest product area and benefits from active rate markets and hedging demand. Periods of macro uncertainty and shifting central-bank policy tend to lift volumes, making CME a structural beneficiary of market volatility. The October 2026 backdrop, with markets repricing the odds of a Federal Reserve move under Chair Kevin Warsh, is the kind of rate uncertainty that tends to keep SOFR and Treasury futures busy.
3. High margins and shareholder returns
Operating margins run near 65 to 70 percent, and the asset-light model converts revenue into substantial free cash flow. CME returns most of that cash through a regular quarterly dividend plus a variable year-end dividend, giving it an unusually high blended payout among large-cap financials.
4. New products and market data
CME continues to extend into event contracts, crypto derivatives, micro-sized contracts for retail, and growing market-data and information-services revenue. These add optionality and diversify the mix beyond the core institutional futures franchise. In October 2026 CME said it was launching futures on Uniswap and Bitcoin Cash, widening its crypto lineup beyond bitcoin, ether and other major tokens.
The bear case: what would have to be true for $218.00
The most pessimistic published target is $218.00, -25.8% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks CME Group is worth if the risks below bite instead of the drivers above.
Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Competition is intensifying: FMX targets U.S. Treasury and SOFR futures with LCH clearing, ICE dominates Brent energy, and Cboe leans on VIX and options flow. A newer threat is regulated perpetual futures from crypto venues such as Coinbase and Kalshi, which the market fears could eventually breach the regulatory moat protecting high-margin retail products like 0DTE options. The stock also trades at a premium exchange multiple, so any volume slowdown or fee compression can weigh on the shares. Growth slowed sharply in the second quarter of 2026, with revenue up less than 1% year over year, and consensus calls for ~10% EPS growth in 2026 and ~6% in 2027, which leaves a ~22x forward multiple with limited room for a volume slump.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CME already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CME
16 analysts cover CME, with an average target of $292.94 (-0.3% against $293.87) and a split of 8 buy, 6 hold, 3 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CME forecast and price target page.
How is CME valued? (as of October 2026)
Snapshot for CME as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$6.76B (FY2025 ~$6.52B); Q2 2026 +~0.8% y/y
- Net income (TTM): ~$4.26B, profit margin ~63%
- Operating margin: ~65%
- EPS (TTM / 2026 est.): ~$11.79 trailing; ~$12.31 consensus for 2026
- P/E trailing / forward: ~24.7x / ~22.4x
- Market cap: ~$104.6B at ~$290.98 (16 Oct 2026)
- Dividend yield: ~1.8% regular ($5.20/yr), before the variable year-end dividend
CME has rerated upward since mid-2026, gaining ~23% in three months, so the trailing P/E has moved from about 21 to about 25 even though second-quarter revenue grew less than 1%. Analysts' mean target of ~$293 sits close to the share price, consistent with a hold consensus. The regular dividend alone yields ~1.8%; the variable year-end dividend, declared each December, adds to that and makes the headline blended yield materially higher.
How do you decide if CME is a buy?
Rather than asking whether CME is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CME indirectly through an index or sector ETF before adding more.
What would change your mind on CME
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Record trading volumes stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CME stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CME against your real portfolio and see your actual exposure before deciding.
Investing in CME Group with AI
Connect the broker you already use and ask Walnut's AI how CME fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is CME a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Record trading volumes, with revenue (ttm) at ~$6.76B (FY2025 ~$6.52B); Q2 2026 +~0.8% y/y. The bear case rests on revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Analysts covering it are spread from $218.00 to $337.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CME?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $218.00, -25.8% from the $293.87 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for CME?
+
Record trading volumes. Average daily volume hit a record 36.2 million contracts in Q1 2026, up 22 percent year over year with records across all six asset classes, and revenue reached a record ~$1.88 billion. The most optimistic analyst target on CME is $337.00, +14.7% from the $293.87 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for CME?
+
Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Competition is intensifying: FMX targets U.S. Treasury and SOFR futures with LCH clearing, ICE dominates Brent energy, and Cboe leans on VIX and options flow. A newer threat is regulated perpetual futures from crypto venues such as Coinbase and Kalshi, which the market fears could eventually breach the regulatory moat protecting high-margin retail products like 0DTE options. The stock also trades at a premium exchange multiple, so any volume slowdown or fee compression can weigh on the shares. Growth slowed sharply in the second quarter of 2026, with revenue up less than 1% year over year, and consensus calls for ~10% EPS growth in 2026 and ~6% in 2027, which leaves a ~22x forward multiple with limited room for a volume slump. The most pessimistic published target is $218.00, -25.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does CME Group do?
+
CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals an
What would have to change for CME to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Record trading volumes) stalling in the reported numbers rather than in the narrative, the risk above (revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does CME Group do?
+
CME Group operates the world's largest derivatives marketplace, running futures and options exchanges and a clearinghouse across six asset classes: interest rates, equity indexes, energy, agriculture, metals and foreign exchange. It earns fees on every contract traded and cleared, plus market-data revenue.
How does CME Group make money?
+
The bulk of revenue comes from clearing and transaction fees charged per contract, which reached about $1.54 billion in Q1 2026. The rest comes from market-data and information services, giving CME a mix of volume-driven and recurring subscription revenue. Trailing twelve-month revenue was ~$6.76 billion as of October 2026, at an operating margin near 65%.
What were CME Group's latest results?
+
The most recent quarter, Q2 2026, brought revenue of ~$1.71 billion, up less than 1% year over year, and adjusted EPS of ~$2.99 versus ~$2.91 expected. That followed a record Q1 2026, when revenue reached about $1.88 billion, up 14 percent, adjusted EPS was $3.36, and average daily volume hit a record 36.2 million contracts. Q3 2026 results are scheduled for 21 October 2026, with consensus at ~$2.98 a share.
Walnut is informational, not investment advice, and gives no verdict on CME. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature CME
CME is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.